Bochum, Germany-based Protagen has appointed Christoph H ls CEO and head of the management board, the contract proteomics research company said last week. In addition, Helmut Meyer, a co-founder of the company, will take the position of chief scientific officer, and Martin Bl ggel, another co-founder, will serve as chief operating officer.
H ls has previous management positions with Aventis and Novartis, where he worked in preclinical development, project management, and business development, Protagen said in a statement. The company, founded in 1999, offers protein analysis services including 2D gel and HPLC separation, Edman sequencing, and MALDI-PSD and MS/MS mass spectrometry capabilities.
AxCell Biosciences has added Axel Ullrich, the head of the molecular biology department at the Max Planck Institute for Biochemistry in Martinsried, Germany, to its board of directors, the Newtown, Penn.-based company said last week.
Ullrich is an expert in cellular communication and cancer, AxCell said in a statement, and has experience as a biotech entrepreneur, having co-founded Sugen in 1991, and Axxima Pharmaceuticals in 1998. Ullrich’s appointment “brings a wealth of research expertise, cell signaling knowledge and recognition that will greatly benefit the progression of AxCell as a leading provider of signal transduction pathway information,” said AxCell interim CEO Michael Becker in a statement.
Startup protein microarray company Protometrix has hired Holly Kleinert to serve as president, taking over for Mike Sherman, who has held the position of acting president since the company was founded last year.
Kleinert, who previously oversaw the cardiovascular program at Searle, took the helm of the 15 employee Guilford, Conn.-based company March 1. “We wanted to find somebody with big pharma experience since they’re our most-likely clients, and we wanted someone who can relate best to their needs,” Sherman said in an interview with GenomeWeb.
Peter Chambre, Celera’s former chief operating officer, has joined Cambridge Antibody Technology as CEO, CAT said last week. He is slated to start sometime in April.
Chambre, who left his position at Celera in October to take an undisclosed job at Applera, will lead CAT as it attempts to transform itself into a profitable biopharmaceutical business, the company said in a statement. While Chambre has not had extensive experience in biopharmaceuticals, John Aston, CAT’s chief financial officer, told GenomeWeb that “in the end we decided that it wasn’t essential to have someone with a therapeutics background for this position.”
Correction: In the 2-25-02 issue of ProteoMonitor, the article, ““Proteomics without Pathology and Clinical Data Will Fail”: Swiss Meeting,” incorrectly stated that Europroteome’s algorithm for predicting colorectal cancer patient prognosis was based on data collected from 135 patients. In fact, Europroteome’s team of 40-odd clinicians from research hospitals across Europe compiled pathology and clinical information (134 variables) from 645 patients undergoing surgery for phase I colorectal cancer.